Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod

Executive Summary

Teva has ambitions to file in 2018 after the Phase III CONCERTO trial reads out in 2017. Firm is studying a higher dose of the drug and relying on a different primary endpoint, hoping to show stronger efficacy over a Phase III trial that failed in 2011.

Advertisement

Related Content

Teva Faces Laquinimod Setback After High Dose Linked To CV Events
Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity
Disappointing BRAVO Data Raise Doubts About Laquinimod's Chances With FDA
No Homerun, But A Base Hit For Teva's Laquinimod

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel